Medicine Platform
搜索
Product Catagories
Semaglutide
单价 面议对比
询价 暂无
发货 全国
过期 长期有效
更新 2025-08-14 11:49
 
详细信息

Grade: Pharmaceutical Grade

Factory Location: Quanzhou

Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa

Sample Provided: no

Payment Terms: L/C

On September 20, 2019, the FDA officially approved the marketing application of semaglutide for improving blood sugar control in patients with type 2 diabetes in combination with diet and exercise. Semaglutide is a human GLP-1 analogue with high albumin affinity and a long half-life, enabling once-weekly administration to stimulate insulin secretion and inhibit glucagon secretion in a blood sugar-dependent manner.